This personalized approach is the gold standard for using these powerful medications
[11] The previous term PCOS was considered "inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing." The new term reflects "the condition's multisystem pathophysiology", and is more accurate by omitting cysts
Coverage may also depend on whether a patient meets medical requirements for the medication
Supporting access to GLP-1s may help improve employee health outcomes
AAS, anabolic-androgenic steroid
Sustainable results are achieved with continued use and lifestyle support